PubRank

Kevin H Mayo

Author PubWeight™ 59.82‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A 2006 2.26
2 Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009 2.15
3 Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007 2.13
4 Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006 1.82
5 Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006 1.76
6 Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J 2007 1.23
7 The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res 2003 1.22
8 Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett 2010 1.16
9 Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer 2005 1.13
10 Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 2006 1.11
11 The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J 2002 1.09
12 Promotion of peptide antimicrobial activity by fatty acid conjugation. Bioconjug Chem 2004 1.07
13 Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem 2004 1.06
14 Acylation of SC4 dodecapeptide increases bactericidal potency against Gram-positive bacteria, including drug-resistant strains. Biochem J 2004 1.04
15 Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J Natl Cancer Inst 2006 1.03
16 Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett 2003 1.03
17 CXC and CC chemokines form mixed heterodimers: association free energies from molecular dynamics simulations and experimental correlations. J Biol Chem 2008 1.02
18 Lactose binding to galectin-1 modulates structural dynamics, increases conformational entropy, and occurs with apparent negative cooperativity. J Mol Biol 2010 1.02
19 Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene. Bioconjug Chem 2010 1.02
20 Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem 2012 1.00
21 Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res 2011 0.98
22 A journey in structure-based drug discovery: from designed peptides to protein surface topomimetics as antibiotic and antiangiogenic agents. Acc Chem Res 2007 0.98
23 Metastin (KiSS-1) mimetics identified from peptide structure-activity relationship-derived pharmacophores and directed small molecule database screening. J Med Chem 2007 0.98
24 1H, 13C, and 15N backbone and side-chain chemical shift assignments for the 29 kDa human galectin-1 protein dimer. Biomol NMR Assign 2008 0.96
25 Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Lett 2008 0.95
26 The alpha-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain. Glycobiology 2009 0.95
27 The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin-glycan interactions at the cell surface. Biochem J 2009 0.94
28 Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J Control Release 2011 0.92
29 Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil Steril 2005 0.91
30 Topomimetics of amphipathic beta-sheet and helix-forming bactericidal peptides neutralize lipopolysaccharide endotoxins. J Med Chem 2006 0.90
31 Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biochem J 2003 0.89
32 The nociceptin pharmacophore site for opioid receptor binding derived from the NMR structure and bioactivity relationships. J Biol Chem 2004 0.87
33 Anginex-conjugated liposomes for targeting of angiogenic endothelial cells. Bioconjug Chem 2007 0.87
34 Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay. Int J Clin Oncol 2007 0.87
35 Tumour thermotolerance, a physiological phenomenon involving vessel normalisation. Int J Hyperthermia 2011 0.87
36 Using pulse field gradient NMR diffusion measurements to define molecular size distributions in glycan preparations. Carbohydr Res 2009 0.86
37 Structural aspects of binding of α-linked digalactosides to human galectin-1. Glycobiology 2011 0.86
38 NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Mol Cancer Ther 2009 0.85
39 Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem Biophys Res Commun 2006 0.84
40 Heat capacities and a snapshot of the energy landscape in protein GB1 from the pre-denaturation temperature dependence of backbone NH nanosecond fluctuations. J Mol Biol 2003 0.83
41 Measuring protein self-diffusion in protein-protein mixtures using a pulsed gradient spin-echo technique with WATERGATE and isotope filtering. J Magn Reson 2004 0.83
42 (1)H, (13)C, and (15)N backbone and side-chain chemical shift assignments for the 36 proline-containing, full length 29 kDa human chimera-type galectin-3. Biomol NMR Assign 2014 0.83
43 Discovery and development of anti-angiogenic peptides: A structural link. Angiogenesis 2003 0.83
44 Structural features for α-galactomannan binding to galectin-1. Glycobiology 2011 0.83
45 Comparison of (13)C(alpha)H and (15)NH backbone dynamics in protein GB1. Protein Sci 2003 0.82
46 NMR solution structure of the angiostatic peptide anginex. Biochim Biophys Acta 2007 0.82
47 Probing structure-activity relationships in bactericidal peptide betapep-25. Biochem J 2008 0.82
48 Cloning an artificial gene encoding angiostatic anginex: From designed peptide to functional recombinant protein. Biochem Biophys Res Commun 2005 0.82
49 Aqueous gel formation of a synthetic peptide derived from the beta-sheet domain of platelet factor-4. Biomacromolecules 2002 0.81
50 The antiangiogenic properties of bactericidal/permeability-increasing protein (BPI). Ann Med 2002 0.79
51 A simple method to measure 13CH2 heteronuclear dipolar cross-correlation spectral densities. J Magn Reson 2004 0.79
52 Lactose binding to human galectin-7 (p53-induced gene 1) induces long-range effects through the protein resulting in increased dimer stability and evidence for positive cooperativity. Glycobiology 2013 0.79
53 1H, 13C, and 15N backbone and side-chain chemical shift assignments for the 31 kDa human galectin-7 (p53-induced gene 1) homodimer, a pro-apoptotic lectin. Biomol NMR Assign 2011 0.78
54 p16(INK4a) Peptide mimetics identified via virtual screening. Bioorg Med Chem Lett 2009 0.78
55 Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. Invest New Drugs 2013 0.77
56 Identification of novel drug targets for angiostatic cancer therapy; it takes two to tango. Curr Pharm Des 2007 0.77
57 Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1. J Pharmacol Exp Ther 2012 0.76
58 Protein dynamics using frequency-dependent order parameters from analysis of NMR relaxation data. J Magn Reson 2003 0.76
59 Structure/function studies of an endotoxin-neutralizing peptide derived from bactericidal/permeability-increasing protein. Surgery 2004 0.76
60 Defining the potential of aglycone modifications for affinity/selectivity enhancement against medically relevant lectins: synthesis, activity screening, and HSQC-based NMR analysis. Chembiochem 2014 0.76
61 Protein lysine-Nζ alkylation and O-phosphorylation mediated by DTT-generated reactive oxygen species. Protein Sci 2013 0.75
62 Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with Pseudomonas aeruginosa. Biochim Biophys Acta 2013 0.75